Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News
LucidSearch
QuickAnswers

Contact Us

Search

Sleep Apnea

ERS 2025 Preview: Key Respiratory Highlights to Watch

ERS 2025 at a glance Ahead of ERS 2025 in Amsterdam, get concise highlights…

by Matina Laloumi

Public_Health

Public Health Weekly News - August 14th 2025

🔬 Public Health Update: SuperAgers, Tick Bite Surge, Cancer-Fighting Workouts,…

Public_Health

Public Health Weekly News - May 23rd 2025

🧠 Public Health Breakthroughs: Alzheimer’s Blood Test, RSV, Sleep Apnea &…

Cardiovascular

Cardiovascular Weekly News - April 24th 2025

❤️ Breaking Cardiovascular News: AI, Diagnostics & Life-Saving Therapies!……

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Rare Disease News
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Obesity Review 2025: The Rise of Oralization, the Muscle Question, and a New Era of Access Pressure
Lucid Diligence Brief: Truemed $34m Series A to scale payment integration platform
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal
Oncology 2025 Review: Curative-Intent Expansion, ADC Acceleration, and the Operationalization of Immunotherapy
Lucid Diligence Brief: BioMarin to acquire Amicus Therapeutics for $4.8B

Tags

Annamycin API manufacturing AstraZeneca Enhertu ATyr Pharma CAP-002 cardiac amyloidosis cardiac rehabilitation Carmot Cedars-Sinai corticosteroids DHEA-S DYSF ELI-002 Eli Lilly TuneLab European Society of Cardiology everolimus exclusivity fam-trastuzumab deruxtecan FDA CRL FORTE GLP-1R IBTROZI iCARE individualized assessments Imperative Care lupus nephritis Mandos Health MAVENCLAD Microplastic exposure Neuralink BCI Neuvosyn NHG nmCRPC OX40 OX40L Prefusion F Preterm birth Quebec quetiapine XR Rgenta Therapeutics Strive Health Syndax Uplizna vimseltinib WAYPOINT World Health Organization

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Obesity Review 2025: The Rise of Oralization, the Muscle Question, and a New Era of Access Pressure
Lucid Diligence Brief: Truemed $34m Series A to scale payment integration platform
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal
Oncology 2025 Review: Curative-Intent Expansion, ADC Acceleration, and the Operationalization of Immunotherapy
Lucid Diligence Brief: BioMarin to acquire Amicus Therapeutics for $4.8B

TAGS

Annamycin API manufacturing AstraZeneca Enhertu ATyr Pharma CAP-002 cardiac amyloidosis cardiac rehabilitation Carmot Cedars-Sinai corticosteroids DHEA-S DYSF ELI-002 Eli Lilly TuneLab European Society of Cardiology everolimus exclusivity fam-trastuzumab deruxtecan FDA CRL FORTE GLP-1R IBTROZI iCARE individualized assessments Imperative Care lupus nephritis Mandos Health MAVENCLAD Microplastic exposure Neuralink BCI Neuvosyn NHG nmCRPC OX40 OX40L Prefusion F Preterm birth Quebec quetiapine XR Rgenta Therapeutics Strive Health Syndax Uplizna vimseltinib WAYPOINT World Health Organization

Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News
LucidSearch
QuickAnswers

© 2025 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy